Clinical Trial Update: An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating ulocuplumab plus low-dose cytarabine in newly diagnosed acute myeloid leukemia was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Low-dose cytarabine (Cytarabine (low-dose))
• Ulocuplumab (ulocuplumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-09-16